Skip to main content

Table 1 Baseline demographic and clinical characteristics of eligible HIV-1-infected patients

From: Virological failure of staggered and simultaneous treatment interruption in HIV patients who began Efavirenz-based regimens after allergic reactions to nevirapine

   EFV-based regimens  
  Available data (n) Simultaneous Interruptiona Staggered Interruptionb Controlsc p valued
Total number, n 559 161 82 316  
Mean age, years (SD) 559 41.8 (8.3) 39.4 (9.4) 43.0 (8.4) 0.003
Female, % 559 39.1 59.8 33.9 <0.001
Mean body weight, kilograms (SD) 556 54.9 (9.2) 54.8 (9.8) 56.9 (12.4) 0.091
History of previous major opportunistic infections, % 556 40.6 35.4 51.9 0.007
History of previous allergic reactions to other drugs (exclude NVP), % 555 32.7 30.9 11.4 <0.001
Median duration of previous NVP-based regimens, days (IQR) 234 14 (11,27) 14 (12, 30)   0.574
Median baseline of CD4 cell count, cells/uL (IQR) e 543 69 (24, 140) 90 (26, 167) 47 (13, 132) 0.006
Baseline plasma HIV-1 RNA >100,000 copies/ml, % e 258 69.6 77.4 76.0 0.595
Baseline EFV-based regimens      
-Once-daily regimen,% 556 0.6 2.5 13.7 <0.001
-OBRs 559     
D4T/3TC, %   93 73 58  
AZT/3TC, %   6 24 23  
TDF/3TC, %    2 11  
  1. Note: AZT = Zidovudine; D4T = Stavudine; EFV = Efavirenz; IQR = Interquartile range; NVP = Nevirapine; OBRs = Optimized background regimens; SD = Standard deviation; TDF = Tenofovir; 3TC = Lamivudine.
  2. aHIV-1-infected patients who simultaneously discontinued all drugs in NVP-based regimens when they experienced allergic reactions to NVP-based regimens.
  3. bHIV-1-infected patients who discontinued NVP first but continued use of the other NRTIs for a few days when they experienced allergic reactions to NVP-based regimens.
  4. cHIV-1-infected patients who were naïve to antiretroviral therapy and were never exposed to NVP before beginning EFV-based regimens.
  5. dp-value represents the difference between the three groups (Simultaneous interruption, Staggered interruption, and Control).
  6. eThese results would be included if they were examined within 6 months before starting EFV-based regimens.